{"id":7145,"date":"2023-11-30T15:22:06","date_gmt":"2023-11-30T21:22:06","guid":{"rendered":"https:\/\/labtesting.\/?p=7145"},"modified":"2023-11-30T15:24:25","modified_gmt":"2023-11-30T21:24:25","slug":"elispot-assays-the-key-to-unlocking-advanced-cellular-immunity-testing","status":"publish","type":"post","link":"https:\/\/labtesting.\/2023\/11\/30\/elispot-assays-the-key-to-unlocking-advanced-cellular-immunity-testing\/","title":{"rendered":"ELISpot Assays: The Key to Unlocking Advanced Cellular Immunity Testing"},"content":{"rendered":"\n

The rise of gene therapies, cell therapies and advanced vaccine research has increased the demand for cellular immunity testing in a regulated environment to ensure the safety and efficacy of these treatments. However, cellular immunity testing is more complex than traditional immunoassays, as cell culture is included. ELISpot assays can overcome challenges associated with this testing and redefine our approach to cellular immunogenicity. <\/p>\n\n\n\n

How ELISpot assays overcome challenges in immunogenicity testing<\/h3>\n\n\n\n

Infection, natural exposure and immunization induce a response by the body’s T cells. These cells learn and proliferate effector functions, so when they are faced with the same antigen, they secrete cytokines they were instructed to produce when they were first primed. ELISpot assays, first developed in 1988 by Cecil Czerkinsky, visualize the secretion of individual cells, testing the frequency of cells that produce cytokines, making it the most sensitive and effective tool for direct in vitro<\/em> detection of antigen-specific T cells. <\/p>\n\n\n\n

ELISpot assays address several limitations in cellular immunogenicity testing through the significant advantages they offer, including: <\/p>\n\n\n\n